GVS S.p.A. (LON:0GV5)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 787.37M -2.8% |
| Revenue (ttm) | 365.19M -1.2% |
| Net Income | 35.13M +165.3% |
| EPS | 0.19 +159.8% |
| Shares Out | n/a |
| PE Ratio | 22.41 |
| Forward PE | 17.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 123,005 |
| Open | 4.820 |
| Previous Close | 4.713 |
| Day's Range | 4.820 - 4.860 |
| 52-Week Range | 3.365 - 4.995 |
| Beta | 1.17 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About GVS S.p.A.
GVS S.p.A., together with its subsidiaries, produces and sells filter solutions for applications in the healthcare and life sciences, energy and mobility, and health and safety sectors in Italy and internationally. The company offers health and safety products, such as hand dryer and vacuum cleaner filters; nailstation COSMO products; fume extraction and HVAC building products; and disposable masks, half masks, integra masks, powered air purifying respirators, face fit testing, replacement filters, supplied air respirators, spare parts, and acc... [Read more]
Financial Performance
In 2025, GVS S.p.A.'s revenue was 424.66 million, a decrease of -0.91% compared to the previous year's 428.54 million. Earnings were 18.43 million, a decrease of -44.77%.
Financial numbers in EUR Financial StatementsNews
GVS S.p.A. Transcript: Investor update
Guidance for 2026–2028 is raised, with mid-single-digit organic growth and EBITDA margin expansion to 27% by 2028. Strategic focus is on organic growth, innovation, and operational excellence across all divisions, with no M&A planned and leverage targeted at 1.0x. Product innovation and market share gains in MedTech, Safety, and hydrogen membranes are key growth drivers.
GVS S.p.A. Press release: Investor update
GVS S.p.A. issued a press release on September 24, 2026, disclosing material business information to investors.
GVS S.p.A. Slides: Investor update
GVS S.p.A. has posted slides in relation to its latest quarterly earnings report, which was published on September 24, 2026.
GVS S.p.A. Earnings Call Transcript: Q2 2026
Sales grew 3.3% year-over-year to EUR 215 million, with EBITDA up 2.2% and margin expansion to 25.7%. All divisions posted organic growth, led by transfusion medicine and safety, while guidance for low single-digit growth and margin improvement is reaffirmed amid ongoing geopolitical caution.
GVS S.p.A. Earnings release: Q2 2026
GVS S.p.A. released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
GVS S.p.A. Slides: Q2 2026
GVS S.p.A. has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
GVS S.p.A. Quarterly report: Q2 2026
GVS S.p.A. has published its Q2 2026 quarterly earnings report on August 6, 2026.
GVS S.p.A. Earnings Call Transcript: Q1 2026
Q1 2026 saw 3.9% organic revenue growth to €105 million, with adjusted EBITDA margin up 57 bps and net income at €10.7 million. Healthcare, Life Science, and Safety divisions led growth, while Mobility stabilized. Guidance remains for low single-digit sales growth and margin expansion.
GVS S.p.A. Earnings release: Q1 2026
GVS S.p.A. released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
GVS S.p.A. Slides: Q1 2026
GVS S.p.A. has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
GVS S.p.A. Quarterly report: Q1 2026
GVS S.p.A. has published its Q1 2026 quarterly earnings report on May 14, 2026.
GVS S.p.A. Earnings Call Transcript: Q4 2025
Sales grew 2% year-over-year excluding FX, with adjusted EBITDA up 3% and margin at 25.2%. Guidance for 2026 is low single-digit growth, 20-50 bps EBITDA margin improvement, and a leverage ratio of 1.8, amid ongoing FX and raw material risks.
GVS S.p.A. Earnings release: Q4 2025
GVS S.p.A. released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
GVS S.p.A. Slides: Q4 2025
GVS S.p.A. has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 26, 2026.
GVS S.p.A. Annual report: Q4 2025
GVS S.p.A. has published its Q4 2025 annual report on March 26, 2026.
GVS S.p.A. Earnings Call Transcript: Q3 2025
Healthcare and life science and safety divisions delivered strong growth, while mobility lagged. Adjusted EBITDA margin and net income improved year-over-year, with guidance for continued margin expansion and cash generation in Q4. FX, US dialysis, and working capital were key headwinds.
GVS S.p.A. Earnings release: Q3 2025
GVS S.p.A. released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.
GVS S.p.A. Slides: Q3 2025
GVS S.p.A. has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 12, 2025.
GVS S.p.A. Quarterly report: Q3 2025
GVS S.p.A. has published its Q3 2025 quarterly earnings report on November 12, 2025.